The business diversification will allow the Hyderabad-based vaccine maker to produce leading-edge regenerative and personalised therapies for Indian patients at an affordable cost.
“Bharat aims to democratise gene therapies, traditionally considered prohibitively expensive and available primarily in developed nations or premium institutions,” said Raches Ella, chief development officer at Bharat Biotech, who is spearheading the CGT (cell and gene therapy) initiative. “Our CGT facility is designed to produce high-titer viral vectors like AAV, lentivirus and adenovirus, which are essential for cell and gene therapy applications – the crucial material for anti-cancer and genetic disorders and robust clinical development abilities,” he said.
As per Bharat Biotech, the facility will tackle scientific challenges such as targeted gene expression, immune system modulation, and long-term cell survival. Work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia.
